Projektbeschreibung
Neuartige Nanomedizin gegen Bauchspeicheldrüsenkrebs
Bauchspeicheldrüsenkrebs gilt als eine der aggressivsten Krebsarten, die im frühen Stadium oft unerkannt bleibt, weil es keine spezifischen Symptome gibt. Dieser Krebs ist durch eine insgesamt schlechte Prognose, eine niedrige Überlebensrate und begrenzte Behandlungsmöglichkeiten gekennzeichnet. Um den Betroffenen Behandlungsalternativen zu bieten, verfolgt das EU-finanzierte Projekt NoCanTher das Ziel, Nanopartikel zu entwickeln, die auf eine Weise funktionalisiert werden, dass sie Bauchspeicheldrüsenkrebszellen angreifen und ein Antikrebsmedikament verabreichen. Die Forschenden treiben die Ausarbeitung dieser Nanoformulierung für die klinische Entwicklung voran, wozu auch die Skalierung der Produktion unter zertifizierten Bedingungen und die Optimierung verschiedener Parameter für den Einsatz bei den Patientinnen und Patienten gehören.
Ziel
This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.
The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.
NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:
• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process.
• Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).
This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).
Wissenschaftliches Gebiet
- medical and health sciencesclinical medicineoncologyprostate cancer
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesclinical medicineoncologybreast cancer
- engineering and technologynanotechnologynano-materials
- medical and health sciencesclinical medicineoncologypancreatic cancer
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-NMP-2015-two-stage
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
28049 Madrid
Spanien